Truong Mylene T, Munden Reginald F, Movsas Benjamin
Department of Diagnostic Radiology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
J Am Coll Radiol. 2004 Dec;1(12):957-64. doi: 10.1016/j.jacr.2004.07.007.
Accurately staging patients with lung cancer is important in determining treatment options and prognoses. Staging allows the distinction of patients who are candidates for surgical resection from those with inoperable disease who may be treated with chemotherapy and/or radiation therapy. Conventional imaging plays an essential role in the noninvasive and invasive methods of the evaluation and staging of patients with non-small-cell lung cancer (NSCLC). Imaging modalities used for staging include chest radiography, chest computed tomography (CT), abdominal CT, brain CT or magnetic resonance imaging, bone scans, and (18)F-2-deoxy-d-glucose positron emission tomography (PET). Recently, PET/CT, the integration of the functional data of PET with the anatomic data of CT, has emerged as a modality to potentially change the way patients are evaluated. This article reviews current recommendations regarding the staging of patients with NSCLC and addresses the role of PET/CT.
准确对肺癌患者进行分期对于确定治疗方案和预后至关重要。分期有助于区分适合手术切除的患者与可能接受化疗和/或放疗的无法手术的患者。传统影像学在非小细胞肺癌（NSCLC）患者评估和分期的非侵入性和侵入性方法中起着至关重要的作用。用于分期的影像学检查包括胸部X线摄影、胸部计算机断层扫描（CT）、腹部CT、脑部CT或磁共振成像、骨扫描以及（18）F-2-脱氧-D-葡萄糖正电子发射断层扫描（PET）。最近，PET/CT，即PET的功能数据与CT的解剖数据相结合，已成为一种可能改变患者评估方式的检查手段。本文回顾了关于NSCLC患者分期的当前建议，并阐述了PET/CT的作用。
